As the number of patients suffering from such disorders increase, so does the demand for more convenient and patient-friendly drug delivery systems.
TORONTO (PRWEB) May 25, 2023
Chronic clinical conditions are among the leading causes of death and disability globally. Typically, individuals are required to medicate on a daily, weekly and/or monthly basis. Now more than ever, patients want to make treatment a smaller part of their life. The development and commercialization of self-administrable medicinal products outside a clinic, hospital or healthcare provider environment, is an attractive alternative for healthcare expenditure and patients because of the flexibility and desire to reduce clinic visits. As the number of patients suffering from such disorders increase, so does the demand for more convenient and patient-friendly drug delivery systems.
Over the past five years, significant improvements have been made to address dose volumes and treatment options, such as monoclonal antibody-based therapies. These treatments often have viscous, highly concentrated drug formulations that require higher doses and delivery volumes that are typically outside the range of standard syringe capabilities. Novel drug delivery technologies are being introduced, specifically, large volume, on-body drug delivery systems. The novelty of these solutions has increased the complexity of regulations and particularly how to navigate the regulations from a global perspective.
Currently, the majority of large volume wearable injectors are primarily present in North America and Europe, within which the principal global regulatory frameworks are led by, or based on, the United States and European regulations. These large-volume on-body delivery systems are typically co-packaged with pre-filled drug cartridges i.e., co-packaged combination products.
However, the pathway to approval differs between the US and Europe which can lead to diverse, complex regulatory strategies when developing a product that must meet both regulatory frameworks.
Register to learn about on-body drug delivery systems and addressing their complex global regulatory requirements.
Join experts from West Pharmaceutical Services, Inc., Paul Scannell, Director Regulatory Affairs Combination Products, EU; and Adam Coblentz, Principal, Regulatory Affairs Intelligence, for the live webinar on Thursday, June 15, 2023, at 10am EDT (4pm CEST/EU-Central).
For more information, or to register for this event, visit Drug Delivery — Addressing Global Regulatory Challenges in Co-Packaged, On-Body Systems.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Tel: +1 (416) 977-6555 x371